<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517738</url>
  </required_header>
  <id_info>
    <org_study_id>CIIBH-Ref.1639/GAS 166-09/11-1</org_study_id>
    <nct_id>NCT00517738</nct_id>
  </id_info>
  <brief_title>Effect of Physical Training Program on Health-related Quality of Life in Cirrhosis</brief_title>
  <official_title>Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physical training improves quality of life (QOL) in non-hepatic diseases. It is possible that
      the same effect happens in patients with cirrhosis and portal hypertension. Hepatic
      encephalopathy may also benefit from physical activity by increasing ammonia metabolism. The
      intention of this study is to assess if patients can improve their QOL and hepatic
      encephalopathy during a physical training program, and to address its safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cirrhosis and portal hypertension experience a marked deterioration in
      health-related quality of life (QOL), as it has been shown with the use of questionnaires
      such as Short-Form-36 (SF-36) and Chronic Liver Disease Questionnaire (CLDQ). The
      deterioration in QOL is progressively accentuated as liver failure advances. There is a
      positive association between the level of physical activity and the sense of QOL, and
      physical training programs have proved to be useful in improving QOL in cardiovascular and
      pulmonary diseases, and in conditions affecting cognition. Thereby, it is hypothesized that a
      physical training program may improve QOL and hepatic encephalopathy in patients with
      cirrhosis and portal hypertension. Data supporting physical activity as a way to improve
      hepatic encephalopathy derives from experimental models showing that skeletal muscle is able
      to remove blood ammonia, presumably by inducing the enzyme glutamine synthetase. However, it
      is uncertain whether such a program is safe, or if it can lead to an increase in portal
      hypertension and progression of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in QOL questionnaires</measure>
    <time_frame>3 months</time_frame>
    <description>QOL will be measured by means of SF-36 and CLDQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lack of deterioration in portal hypertension</measure>
    <time_frame>3 months</time_frame>
    <description>This will be measured by the hepatic vein pressure gradient (HVPG) through liver catheterization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive status</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome will be evaluated with neuropsychological tests: psychometric hepatic encephalpathy score (PHES) and the critical flicker frequency test (CFF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No increase in the rate of variceal bleeding and no progression in the number/size of esophageal varices</measure>
    <time_frame>3 months</time_frame>
    <description>History taking, hemoglobin measurement, and endoscopy for a detailed description regarding number and size of esophageal varices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved ammonia metabolism and decrease in oxidative stress</measure>
    <time_frame>3 months</time_frame>
    <description>Ammonia, glutamine, glutamate, and glutamine synthetase determinations, as well as oxidative carbonylation of protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in physical capacity and exercise tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>Metabolic equivalents (METs) achieved in the treadmill test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Physical training - No encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the physical training program and diet intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - No encephalopathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients not allocated to exercise program, but undergoing diet intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physical training - Early encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Early encephalopathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical training</intervention_name>
    <description>A program of exercising under strict surveillance, with endurance and coordination maneuvers</description>
    <arm_group_label>Physical training - No encephalopathy</arm_group_label>
    <arm_group_label>Physical training - Early encephalopathy</arm_group_label>
    <other_name>Exercise</other_name>
    <other_name>Muscle ammonia metabolism</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet intervention</intervention_name>
    <description>Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema</description>
    <arm_group_label>Physical training - No encephalopathy</arm_group_label>
    <arm_group_label>Control - No encephalopathy</arm_group_label>
    <arm_group_label>Physical training - Early encephalopathy</arm_group_label>
    <arm_group_label>Control - Early encephalopathy</arm_group_label>
    <other_name>Nutritional therapy</other_name>
    <other_name>Diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven or clinically evident cirrhosis

          -  Able to perform exercise

        Exclusion Criteria:

          -  Overt hepatic encephalopathy grades 3 or 4

          -  Cardiovascular complications (pulmonary hypertension, heart failure)

          -  Diabetes mellitus and microangiopathic complications, or under treatment with insulin

          -  Renal failure

          -  Portal hypertension with high risk for variceal bleeding

          -  Hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Ponce de Leon-Rosales, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran / Universidad Nacional Autonoma de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florencia Vargas-Voráckova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán/ Universidad Nacional Autónoma de México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2007</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Andres Duarte-Rojo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

